Viral hepatitis A, B, and C

Clinics in Liver Disease

Volumn 4, Issue 1, 2000, Pages 47-71

  Regev, Arie ^a   Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; FAMCICLOVIR; GANCICLOVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; LAMIVUDINE; LOBUCAVIR; PREDNISOLONE; RIBAVIRIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOBLOTTING; LIVER DISEASE; LIVER TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VIRUS GENOME; VIRUS HEPATITIS; VIRUS INFECTION;

EID: 0034424751     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70096-9     Document Type: Article

References (197)

1. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practice
2. Epidemiology of hepatitis C
3. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
4. Comparison of HAV antibodies induced by vaccination, passive immunization, and natural infection
5. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation
6. Post-transfusion hepatitis A
7. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
8. Jaundice occurring one to four months after transfusion of blood or plasma. Report of 7 cases
9. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
10. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
11. A "new" antigen in leukemia sera
12. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
13. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver disease
14. Efficacy of combined interferon and ribavirin for treatment of hepatitis C
15. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
16. Transient emergence of hepatitis B in patients with chronic hepatitis B resistant to lamivudine
17. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
18. Vaccine-induced escape mutants of hepatitis B virus
19. Comparison of I or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
20. Hepatitis B
21. Predictors of patient and graft survival following liver transplantation for hepatitis C
22. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults
23. Cytotoxic T cells and viral hepatitis
24. Isolation of the cDNA clone derived from a blood borne non-A non-B viral hepatitis genome
25. An epidemic outbreak of hepatitis A among homosexual men in Stockholm. Hepatitis A, a special hazard for the male homosexual subpopulation in Sweden
26. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool
27. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens
28. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
29. Sexual transmission of hepatitis A in homosexual men: Incidence and mechanism
30. Evidence that the genome of hepatitis A virus consists of single-stranded RNA
31. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region
32. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
33. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
34. Hepatitis C virus antibody and liver disease in patients with porphyria cutanea tarda
35. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicenter randomized trial
36. Hepatitis C and hepatocellular carcinoma
37. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B
38. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
39. Quality of life of hepatitis B and C patients after liver transplantation
40. Sexualperinatal transmission of hepatitis C
41. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity-selected from human pancreatic secretory trypsin inhibitor and minibody repertoires
42. A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees
43. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers
44. Fulminant viral hepatitis
45. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
46. Hepatitis B virus precore/core variation and interferon therapy
47. Hepatitis A: Detection by immune electron microscopy of a virus-like antigen associated with acute illness
48. Transfusion associated hepatitis not due to viral hepatitis type A or B
49. Risk factors associated with chronic hepatitis C virus infection: Limited frequency of an unidentified source of transmission
50. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A
51. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation
52. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
53. Relapsing hepatitis A. Review of 14 cases and literature survey
54. Prolonged intrahepatic cholestasis secondary to acute hepatitis A
55. Effect of human interferon on hepatitis B virus infection in patients with chronic active hepatitis
56. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
57. Characterization of an epidemic of hepatitis A virus involving intravenous drug abusers: Infection by needle sharing
58. Re-treatment of chronic hepatitis C with consensus interferon
59. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection
60. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
61. Posttransfusion hepatitis type A
62. Transmission of human hepatitis to marmosets: Further coded studies
63. Hepatitis in marmosets: Induction of disease with coded specimens from a human volunteer study
64. Hepatitis C: The clinical spectrum of disease
65. Fulminant hepatic failure: Summary of a workshop
66. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report
67. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
68. Intrafamilial transmission of hepatitis C virus in hemodialysis patients
69. Surface gene mutants of hepatitis B virus in infants who develop acute chronic infection despite immunoprophylaxis
70. A multistate, foodborn outbreak of hepatitis A: National Hepatitis A Investigation Team
71. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection
72. Protection against hepatitis A by an inactivated vaccine
73. Chronic hepatitis A with persistent viral replication
74. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection
75. Hepatitis B virus DNA in liver and serum of asymptomatic carriers
76. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus
77. Safety and immunogenicity of Hepatitis A vaccine in patients with chronic liver disease
78. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
79. Seroepidemiology of hepatitis A in the United States
80. Hepatitis A
81. Viral hepatitis in a group of Boston hospitals. II. Importance of exposure to shellfish in a nonepidemic period
82. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
83. Early termination of HCV infection by passive anti-HCV transfer in experimentally infected chimpanzees
84. Hepatitis virus: Effect of heat on infectivity and antigenicity of the MS-1 and MS-2 strains
85. Viral hepatitis, type B (MS-2 strain): Studies on active immunization
86. Infectious hepatitis: Detection of virus during the incubation period and in clinically inapparent infections
87. Infectious hepatitis: Studies on the effect of gamma globulin and on the incidence of inapparent infections
88. The natural history of infectious hepatitis
89. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers
90. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
91. Antiviral therapy for hepatitis B and C in Asians
92. A one year trial of lamivudine for chronic hepatitis B
93. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
94. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda
95. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients
96. Long-term follow-up in patients with chronic hepatitis B treated with interferon alfa
97. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease
98. Hepatitis A outbreak among intravenous amphetamine abusers in Finland
99. Vaccines to prevent viral hepatitis
100. Combination therapy for hepatitis C infection
101. Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial
102. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
103. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance
104. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa
105. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection
106. Eine icterus epidemic
107. Transmission of infective hepatitis to human volunteers
108. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
109. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
110. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans
111. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
112. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B
113. The interaction of alcoholic liver disease and hepatitis C
114. Quantitation of hepatitis C virus in liver and peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection
115. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
116. Association of diabetes mellitus and chronic hepatitis C virus infection
117. Infectious hepatitis traced to the consumption of raw oysters: An epidemiologic study
118. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
119. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive immunization
120. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
121. Production of antibody against "Australia antigen" in rabbits
122. Compact organization of the hepatitis B virus genome
123. Hepatitis B viral DNA in infected human liver and in hepatocellular carcinoma
124. Jaundice following administration of human blood products
125. The importance of initiating daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial
126. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men
127. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
128. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
129. Hepatitis B virus contains pre-S gene-encoded domains
130. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
131. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1 and the procoagulant fg 12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
132. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
133. Hepatitis B and C virus sexual transmission among homosexual men
134. Transmission experiments in serum jaundice and infectious hepatitis
135. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
136. Transient selection of hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and fam-ciclovir resistance
137. Immunotherapy of chronic hepatitis B by anti-HBV vaccine
138. Predictive factors for development of cirrhosis in parenterally, acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
139. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
140. A randomized trial of ribavirin and interferon-alpha versus interferon alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment
141. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais
142. Oyster-associated hepatitis. Failure of shellfish certification program to prevent outbreaks. JAMA
143. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
144. Natural history of liver fibrosis progression in patients with chronic hepatitis C
145. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
146. Cutaneous narcotizing vasculitis associated with hepatitis A virus infection
147. Long incubation post transfusion hepatitis without serological evidence of exposure to hepatitis B serum
148. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
149. Hepatitis A among schoolchildren in a US-Mexico border community
150. Randomized, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C
151. Genetic relatedness of hepatitis A virus strains recovered from different geographical regions
152. Epidemiologic patterns of wild-type hepatitis A virus determined by genetic variation
153. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
154. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: A randomized trial
155. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
156. Liver transplantation in European patients with the hepatitis B surface antigen
157. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b
158. A typical clinical manifestations of hepatitis A
159. Hepatitis C and alcohol
160. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
161. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
162. The risk of transfusion-transmitted viral hepatitis
163. Natural history of hepatitis C
164. In vitro inhibition of hepadnavirus polymerases by the triphosphate of BMS-200475 and lobucavir
165. Volunteer blood donors with antibody to hepatitis C virus: Clinical biochemical, virological, and histologic features
166. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
167. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
168. Virus hepatitis
169. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines
170. Characterization and classification of virus particles associated with hepatitis A. II. Type and configuration of nucleic acid
171. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial
172. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C
173. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
174. Hepatitis A virus infections associated with clotting factor concentrate in the United States
175. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
176. Chronic hepatitis B: Interferon-monotherapy or combination with nucleoside analogues?
177. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
178. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
179. Viral causes and management of acute liver failure
180. The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection
181. Clinical outcome after transfusion-associated hepatitis C
182. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
183. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): A comparative study of two dosing schedules
184. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
185. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals
186. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
187. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies
188. A controlled trial of a formalin-inactivated hepatitis. A vaccine in healthy children
189. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination
190. Early HCV RNA values after interferon predict response
191. Impact of alcohol on the histological and clinical progression of hepatitis C
192. Serious hepatitis A: An analysis of patients hospitalized during an urban epidemic in the United States
193. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis
194. Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction
195. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
196. Nephrotic syndrome and acute renal failure associated with hepatitis A virus infection
197. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma